IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#1269
Positioning
Market Dominance
Manufacturing
Measuring And Control Equipment
$513M
Gary M. Owens
Mesa Laboratories, Inc. designs, manufactures, and markets quality control instruments and disposable products. The Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Headcount
680
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Dates updated upon official exchange announcement.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = MLAB ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MLAB MESA LABORATORIES INC /CO/ | 55 | 62 | 75 | 42 | 36.1x | 30.3x | 7.6% | 3.3% | 62.2% | 7.8% | 5.9% | 12.0% | 0.7% | 37.0x | $513M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
MESA LABORATORIES INC /CO/ (MLAB) receives a "Hold" rating with a composite score of 55.0/100. It ranks #1269 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
HQ Base
LAKEWOOD, Colorado
In-line with peers — no strong momentum signal
Trading at a discount to fundamentals — favorable entry valuation
High profitability & efficiency — strong quality floor supports entry
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for MLAB.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 62 | 68 | -6DRAG |
| MOMENTUM | 42 | 32 | +10ALPHA |
| VALUATION | 75 | 77 | -2NEUTRAL |
| INVESTMENT | 31 | 42 | -11DRAG |
| STABILITY | 47 | 38 | +9ALPHA |
| SHORT INT | 67 | 78 | -11DRAG |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy 7.6% (sector -1.9%)
GM 62% vs sector 44%, OM 8% vs sector 3%
Capital turnover N/A, R&D intensity 8.1%
Rev growth 12%, 11yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate MESA LABORATORIES INC /CO/ (MLAB) as a Hold with a composite score of 55.0/100 at a current price of $95.44. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling.
MESA LABORATORIES INC /CO/ holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 55.0/100 places it at rank #1269 in our full universe.
No Moat
Medium
Poor
Undervalued
Gross margins of 62% signal strong pricing power.
Value factor score of 75 suggests attractive pricing.
Stable competitive position in a defensive sector.
Elevated P/E ratio of 36.1x leaves little room for execution misses.
Vulnerability to macroeconomic shocks and interest rate volatility.
MESA LABORATORIES INC /CO/ represents a hold based on multi-factor quantitative performance.
Our model assigns MESA LABORATORIES INC /CO/ a Hold rating, with a composite score of 55.0/100 and 3 out of 5 stars. Ranked #1269 of 7,333 stocks, MLAB presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
With a quality score of 62/100, MLAB shows adequate but unremarkable business quality. The company reports a return on equity of 7.6% (sector avg: -1.9%), gross margins of 62.2% (sector avg: 44.1%), net margins of 5.9% (sector avg: 1.0%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.
MLAB carries a solid value score of 75/100, pointing to an attractively priced stock relative to peers. Key valuation metrics include a P/E ratio of 36.13x, an EV/EBITDA of 30.32x, a P/B ratio of 2.76x. This score suggests reasonable compensation for the risks involved, with potential upside if the market recognizes the stock's underlying worth.
MESA LABORATORIES INC /CO/'s investment score of 31/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 12.0% vs. a sector average of 6.7% and a return on assets of 3.3% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
MLAB is currently showing below-average momentum at 42/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at 12.0% year-over-year, while a beta of 1.41 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
With a stability score of 47/100, MLAB exhibits average financial resilience. Key stability metrics include a beta of 1.41 and a debt-to-equity ratio of 37.00x (sector avg: 0.2x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
MLAB carries a short interest score of 67/100, indicating moderate short selling activity. This is a neutral reading — not enough to signal systemic bearishness, but worth monitoring. Specific risk factors include above-average market sensitivity (beta: 1.41), elevated leverage (D/E: 37.00x), small-cap liquidity risk. At $513M market cap (small-cap), MESA LABORATORIES INC /CO/ offers reasonable institutional liquidity.
MLAB offers a modest dividend yield of 0.7%. While the income contribution is relatively small, even a small dividend signals management's commitment to shareholder returns and can serve as a signal of financial discipline.
MESA LABORATORIES INC /CO/ is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #1269 of 7,333 overall (83rd percentile). Key comparisons include ROE of 7.6% exceeding the -1.9% sector median and operating margins of 7.8% above the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While MLAB currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Key factor gap
Value (75) vs Investment (31) — closing this gap could shift the rating.
EV/EBITDA 165% ABOVE SECTOR MEDIAN
ROE 503% BELOW SECTOR MEDIAN
Gross Margin 41% ABOVE SECTOR MEDIAN (FAVORABLE)
Above 50MA
37.18%
Net New Highs
+51081
OSHA standardizes on Mesa’s DryCal Defender technology for field enforcement as industry faces generational knowledge gap in flow calibrationLAKEWOOD, Colo., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ: MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced a renewed commitment to advancing primary standard calibration technology through its DryCal product line, as occupational health and safety pro
Most readers would already be aware that Mesa Laboratories' (NASDAQ:MLAB) stock increased significantly by 22% over the...
LAKEWOOD, Colo., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its third fiscal quarter (“3Q26”) ended December 31, 2025 (amounts in thousands). 3Q26 Financial Summary – (comparisons are versus the same year ago period Revenues increased 3.6%Non-GAAP organic and core organic revenues1 growth was 3.6% and 1.2%,
DarioHealth (DRIO) delivered earnings and revenue surprises of 66.10% and 3.23%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?